Health and Human Services Secretary Robert F. Kennedy Jr. lambasted federal agencies he accused of being overly influenced by ...

HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

SCHD underperformed the S&P 500 in 2025 but remains highly attractive due to its strong risk-reward profile and dividend ...

In a recent appearance on CNBC’s Squawk on the Street, Jim Cramer discussed President Trump’s tariffs and their impact on the ...

Merck & Co. ($MRK) is betting on acquisitions to offset the looming revenue loss from the upcoming patent expiration of ...

International companies are increasingly inking licensing deals with Chinese biotechs as concerns regarding drug pricing and ...

Neither the mid-stage nor the late-stage trial of Adagene’s drug needs an arm studying the drug as a monotherapy without Merck’s Keytruda, the company said.

Halozyme's ENHANZE technology drives strong near-term growth, but its key patent expires in 2027. Click here to find out why ...

BURLINGTON - MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, confirmed Neoclease as the winner of the 2025 North ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the initiation of the EXPrESSIVE Phase 3 ...

In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in ...